ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0634

Total Interstitial Inflammation Predicts Chronic Kidney Disease Progression in Patients with Lupus Nephritis
Abstract Number: 0635

Blood RNA-sequencing Reveals Complex Immune Dysregulation in ANA-positive Individuals with Distinct Profiles Preceding Progression to SLE versus Stable Autoimmunity
Abstract Number: 0636

Serum Soluble Mediator Signatures of Lupus Nephritis Histological Features and Response to Treatment
Abstract Number: 0637

Reduced IgG Sialic Acid Content: A Distinctive Characteristic of Symptomatic Anti-Nuclear Antibodies Positive Individuals
Abstract Number: 0638

Identification of New Candidate Drugs for SLE Using a Drug Repurposing Transcriptomic Approach on Blood, Skin and Kidney Samples from 3439 Patients
Abstract Number: 0639

Association of Gut Microbiome Streptococcus, Health Status, Cytokines, and HLA Class in Anti-Ro+ Mothers of Children with Neonatal Lupus: Insights into Progression of Clinical Autoimmunity
Abstract Number: 0640

Immune Cell Heterogeneity in Lupus Nephritis Kidneys and Its Relation to Histopathological Features
Abstract Number: 0641

IL-4 Receptor Signaling and IKAROS Transcriptomic Program Maintains Naïve B-cell Quiescence and Antagonizes SLE
Abstract Number: 0642

SLAMF6-SAP Signaling Unit Is Increased in SLE T Follicular Helper Cells
Abstract Number: 0643

Subsetting SLE Patients Based on DNA Methylation at the Time of Disease Flare
Abstract Number: 0644

Long-lived Plasma Cells in the Lupus Bone Marrow Are Imprinted by Interferon
Abstract Number: 0645

Lupus Fibroblasts from Non-lesional Skin Exhibit Exaggerated Responses to Inflammatory Cytokines and Upregulate Pro-fibrotic Collagens in Patients with Scarring Lesions
Abstract Number: 0646

Modulation of Type I IFN Production and Regulatory T Cells by the PKGI/ROCK Signaling Pathway
Abstract Number: 0647

Transcriptomic Analysis of Lupus Nephritis Kidneys Identifies Molecular Endotypes
Abstract Number: 0648

Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].